A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts

Liu, Jin; Dang, Lei; Li, Defang; Liang, Chao; He, Xiaojuan; Wu, Heng; Qian, Airong; Yang, Zhijun; Au, Doris W.T.; Chiang, Michael; Zhang, Bao-Ting; Han, Quan‐Bin; Yue, Kevin K M; Zhang, Hong Qi; Lv, Chen; Pan, Xiaohua; Xu, Jiake; Bian, Zhaoxiang; Shang, Peng; Wang, Tan; Liang, Zicai; Guo, Baosheng; Lü, Aiping; Zhang, Ge

doi:10.1016/j.biomaterials.2015.02.007

Cited by 85 publications

(61 citation statements)

References 33 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a new class of gene regulators, they are correlated with the wide range of biological processes including cell differentiation, growth, migration and invasion by inversely regulating target gene transcription or translation [6][7][8]. Mounting evidence indicates that abnormal expression of miRNAs is emerging as the prominent pathological contributor for bone degeneration-related diseases by regulating the process of osteoclastogenesis and bone resorption [9][10][11]. For example, miR-503 can act as a negative regulator to mediate osteoclast formation and bone resorption, indicating a new therapeutic way for osteoporosis [12].…”

Section: Introductionmentioning

confidence: 99%

miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases

Xia

Yan

et al. 2015

Experimental Cell Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases

Xia

Yan

et al. 2015

Experimental Cell Research

View full text Add to dashboard Cite

“…In a different investigation, Liu et al . established an efficient delivery system of miRNA‐148a antagonist to reduce bone resorption in resorbed surfaces, with minimal off‐target effects. Similarly, Dong et al .…”

Section: Methodsmentioning

confidence: 99%

Role of epigenetics in alveolar bone resorption and regeneration around periodontal and peri‐implant tissues

Asa’ad

Monje

Larsson

2019

European J Oral Sciences

View full text Add to dashboard Cite

Periodontitis and peri‐implantitis are multifactorial diseases characterized by alveolar bone destruction mediated by the host response to a microbial challenge. Alveolar bone resorption mediated by epigenetics could be one of the mechanisms responsible for this destruction of alveolar bone. The relationship between epigenetic modifications and bone metabolism has been thoroughly investigated in bone remodeling, cancer, and rheumatoid arthritis, but evidence is low regarding the relationship between epigenetic modifications and alveolar bone loss related to periodontal and peri‐implant diseases. Therefore, we conducted a review of the pertinent literature based on a priori‐formulated focused questions and a screening strategy, in an attempt to comprehend the role of different epigenetic mechanisms in alveolar bone loss and to determine the current state with respect to their possible therapeutic applications in regenerative medicine. The review showed that the roles of DNA methylation, histone modifications, and non‐coding RNAs in bone loss have been investigated. The results indicate that epigenetic mechanisms can participate in periodontal and peri‐implant alveolar bone breakdown, suggesting their potential as therapeutic targets in alveolar bone regeneration. However, there is still only preliminary information regarding the possible therapeutic utility of these epigenetic mechanisms, suggesting a need for basic and translational research to assess the potential of such mechanisms in promoting alveolar bone regeneration.

show abstract

“…Liu et al . sought to use this D-Asp8 peptide linked to DOTAP-based liposomes to deliver a modulator of miR-148a (antagomiR-148a), for the treatment of OP [123]. One of the functions of miR-148a is to regulate osteoclastogenesis [124], and downregulation of this miRNA with antagomiR-148a can reduce bone resorption.…”

Section: Approaches For Cellular Deliverymentioning

confidence: 99%

“…Using the fluorescence-activated cell sorting technique, they determined that the miR-148a knockdown efficiency was significantly greater in OSCAR-positive cells (i.e., OCs) compared with OSCAR-negative cells (i.e., non-OCs). The in vivo results demonstrated that the linked liposomes with antagomiR-148a significantly attenuated the decrease of bone mineral density and bone volume in OVX-induced mice [123]. …”

Section: Approaches For Cellular Deliverymentioning

confidence: 99%

Development of nanomaterials for bone-targeted drug delivery

Cheng

Chawla

Yang

et al. 2017

Drug Discovery Today

110

View full text Add to dashboard Cite

Bone is one of the major organs of the human body; it supports and protects other organs, produces blood cells, stores minerals, and regulates hormones. Therefore, disorders in bone can cause serious morbidity, complications, or mortality of patients. However, despite the significant occurrence of bone diseases, such as osteoarthritis (OA), osteoporosis (OP), non-union bone defects, bone cancer, and myeloma-related bone disease, their effective treatments remain a challenge. In this review, we highlight recent progress in the development of nanotechnology-based drug delivery for bone treatment, based on its improved delivery efficiency and safety. We summarize the most commonly used nanomaterials for bone drug delivery. We then discuss the targeting strategies of these nanomaterials to the diseased sites of bone tissue. We also highlight nanotechnology-based drug delivery to bone cells and subcellular organelles. We envision that nanotechnology-based drug delivery will serve as a powerful tool for developing treatments for currently incurable bone diseases.

show abstract

A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts

Cited by 85 publications

References 33 publications

miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases

miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases

Role of epigenetics in alveolar bone resorption and regeneration around periodontal and peri‐implant tissues

Development of nanomaterials for bone-targeted drug delivery

Contact Info

Product

Resources

About